Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact of CMV infection in patients with HSCTs or kidney transplants, the interdisciplinary care team managing these patients must have guidance on incorporating novel antiviral therapies into prevention and treatment schemas for CMV.

In this CME Outfitters recorded Grand Rounds series, expert faculty will emphasize the burden of CMV in kidney transplantation and HSCT, review the benefits and limitations of current antiviral agents, and discuss the role of novel antivirals (e.g., letermovir and maribavir) for managing CMV. Additionally, case studies will demonstrate how to integrate novel antivirals into clinical practice to improve quality of care and outcomes.   

Learn more:  | https://www.cmeoutfitters.com/activity/cytomegalovirus-in-stem-cell-and-kidney-transplant-overcoming-the-limitations-of-conventional-antiviral-therapy/